Grifols strengthens itself with biopharmaceutical talent. The Spanish pharmaceutical company specializing in plasma medicines has appointed Jörg Schüttrumpf as the new director of scientific innovation, according to a statement sent by the company.
As head of innovation for the entire Grifols group, Schüttrumpf will focus on accelerating the development of differentiated plasma and non-plasma medicines in key therapeutic areas, strengthening the company’s portfolio. His responsibilities include the entire development cycle of new therapies, from the earliest phase of discovery to the development of clinical trial programs, as well as the creation of strategic alliances and the promotion of advanced technologies.
Since early 2022, Schüttrumpf has held the role of Scientific Innovation at Biotest, where he previously served as Director of Global Research since 2021 and Director of Research and Development since 2015. Under his leadership, the Biotest team has developed therapies based on human plasma, as well as recombinant proteins such as monoclonal antibodies.
Recently, he has focused on the development of three innovative plasma proteins. One of these is Yimmugo, which was approved last year and is an updated version of an immunoglobulin G preparation manufactured using a high-throughput process that results in a treatment with an optimized safety profile. The other two proteins are fibrinogen and trimodulin, plasma therapies with great therapeutic potential that are already being successfully developed in phase 3 clinical trials.
Read more about Grifols and find the most important financial news of the day with our companion app Born2Invest.
Grifols has more than 1,200 people who work together in four global research centers
Schüttrumpf is a physician and scientist specializing in Transfusion Medicine and haemostasisology. He is a graduate of the Goethe University of Frankfurt (Germany), the Albert-Ludwigs University of Freiburg (Germany), and the IMD Business School of Lausanne (Switzerland). Throughout his career, he has worked at research institutions in both Germany and the United States.
“We are convinced that it will elevate Grifols’ innovation for the benefit of our community of patients and stakeholders,” says Víctor Grifols Deu, Grifols’ director of operations.
In recent years, Grifols has invested in its innovation infrastructure and currently has more than 1,200 people who work together in four global research centers. In 2021, the company created the Office of Scientific Innovation to unify the group’s research and development efforts under one umbrella, ensuring project prioritization and global collaboration between teams. Grifols has recently established important technological alliances, such as the agreement with Google Cloud, to promote the use of data and new technologies.
DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.
This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.
First published in PlantaDoce. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.
Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.